CEO Kevin Sharer said yesterday that 2007 earnings should approach $4.30 a share, rather higher than previous estimates of $4.13 to $4.23, the WSJ reports.
Speaking at the J.P. Morgan Healthcare Conference in San Francisco, Sharer said job cuts and other cost cutting “came close to recapturing” the revenue the company lost as sales of its golden-goose anemia-drug franchise fell on safety concerns associated with the drugs.
The company’s stock, which fell by more than 30% last year (see chart), closed up 2% yesterday. But it would be premature to declare 2008 a jubilee year for the company. An FDA advisory panel will meet in March to discuss the use of the company’s anemia drugs in cancer patients — one in a long series of similar meetings. The panel is a big enough deal that Amgen has postponed its big annual business review until after the meeting.
The company’s best hope to get back on the growth track is denosumab, aka D-mab, an experimental osteoporosis drug. But the bone-drug market is a crowded one, and D-mab will need to show stellar results to stand out. TEVA药厂 CFO在26届JPM 健康产业投资论坛上的讲演
SAN FRANCISCO (AP) _ Biotech company Amgen Inc. predicted Tuesday that its cost-cutting would push its 2007 profits higher than it forecast in October.
CAMBRIDGE, Mass. (AP) _ Biotechnology company Genzyme Corp. said Tuesday its fourth-quarter revenue rose 21 percent to top Wall Street expectations, and said annual sales in its kidney and surgical orthopedic segments will reach $1 billion by 2011.
DALLAS (AP) _ Zix Corp. said Tuesday it expects to meet its fourth-quarter sales forecast on strong results from its e-mail encryption and e-prescribing operations. [标签:content1][标签:content2]
作者:admin@医学,生命科学 2011-05-24 17:17